Two manufacturer sponsored phase III trials suggest that alemtuzumab, an anti-CD52 monoclonal antibody that is licensed to treat leukaemia, may help control multiple sclerosis. Both trials lasted two years and compared alemtuzumab with interferon beta-1a, which is considered first line treatment. One trial looked at 563 patients who had not yet undergone treatment for multiple sclerosis, whereas the other trial looked at …
almost 7 years ago
Red Flags typically refer to features that may suggest serious life threatening disease such as malignancy (leukaemia), infection (septic arthritis or osteomyelitis) or non-accidental injury. We also include features that may suggest inflammatory joint or muscle disease.
almost 6 years ago